Y-MABS THERAPEUTICS INC. - COMMON STOCK

Y-mAbs to Announce Third 2021 Financial and Operating Results on November 4, 2021

28 Oct 2021 16:01:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Data to be Presented at SIOP 2021

16 Sep 2021 09:00:01 By Nasdaq GlobeNewswire

Y-mAbs Announces Priority Review of BLA for DANYELZA® (naxitamab-gqgk) in China

13 Sep 2021 09:00:01 By Nasdaq GlobeNewswire

Y-mAbs to Host Key Opinion Leader Webinar on DANYELZA® (naxitamab-gqgk) Frontline and HITS Data in High-Risk Neuroblastoma

10 Sep 2021 09:00:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments

05 Aug 2021 16:01:01 By Nasdaq GlobeNewswire

Y-mAbs to Announce Second Quarter 2021 Financial and Operating Results on August 5, 2021

29 Jul 2021 16:05:01 By Nasdaq GlobeNewswire

Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China

06 Jul 2021 08:37:42 By Nasdaq GlobeNewswire

Y-mAbs’ 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Receives Positive Opinion on Orphan Medicinal Product Designation by EMA

25 Jun 2021 09:00:00 By Nasdaq GlobeNewswire

Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma

23 Jun 2021 09:00:01 By Nasdaq GlobeNewswire

Y-mAbs Announces Frontline Data for DANYELZA® (naxitamab-gqgk) in High-Risk Neuroblastoma

04 Jun 2021 09:05:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Update on Omburtamab for DIPG

04 Jun 2021 09:00:00 By Nasdaq GlobeNewswire

Y-mAbs Enters into Exclusive Distribution Agreement with Adium Pharma S.A. for DANYELZA® (naxitamab-gqgk) and Omburtamab in Latin America

19 May 2021 16:01:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Update on SADA Technology

13 May 2021 09:00:02 By Nasdaq GlobeNewswire

Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments

06 May 2021 16:01:02 By Nasdaq GlobeNewswire

Y-mAbs to Announce First Quarter 2021 Financial and Operating Results on May 6, 2021

29 Apr 2021 16:01:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Data to be Presented at 2021 ASCO Annual Meeting

29 Apr 2021 09:00:02 By Nasdaq GlobeNewswire

Y-mAbs Submits Omburtamab Marketing Authorization Application to the European Medicines Agency

27 Apr 2021 16:01:00 By Nasdaq GlobeNewswire

Y-mAbs Provides Regulatory Update on Omburtamab   

20 Apr 2021 09:00:01 By Nasdaq GlobeNewswire

Y-mAbs Announces GPA33-SADA Data Presented at AACR

12 Apr 2021 09:00:00 By Nasdaq GlobeNewswire

Y-mAbs Announces 2020 Financial Results and Recent Corporate Developments

25 Feb 2021 16:01:00 By Nasdaq GlobeNewswire